The Bill & Melinda Gates Foundation is investing in a pioneering biotech firm developing drugs to fight life-threatening infections.
Arsanis, headquartered in America, has raised $45 million in a new funding drive, led by the Gates Foundation. The money will be used to advance drugs that can combat the growing threat of antibiotic-resistant bacteria.
Rene Russo, the biotech’s chief executive officer hailed the “caliber of investors attracted to Arsanis” as evidence of the faith there in its work to develop “therapies to prevent and treat serious infectious diseases and mitigate the growing global health threat of antimicrobial resistance”.
“Arsanis is poised to make a significant mark on the way serious infections are prevented and treated, particularly in light of the challenges faced globally as more infectious diseases are resistant to available treatments,” said Carl Gordon, founding partner and co-head of global private equity, OrbiMed. “The Arsanis leadership team has the deep expertise needed to succeed, and we are proud to partner with our new investors to support the company’s efforts as it advances promising monoclonal antibodies through clinical development for S. aureus pneumonia and other life-threatening infections.”
This website uses cookies to improve your experience, and also collects some information using Google Analytics. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.